{
  "ticker": "JNJ",
  "target_date": "2025-03-20",
  "actual_date": "2025-03-20",
  "collected_at": "2025-12-08T11:32:30.364483",
  "price": {
    "open": 159.42,
    "high": 159.62,
    "low": 158.38,
    "close": 159.4442138671875,
    "volume": 7485900,
    "change_1d_pct": 0.02,
    "change_7d_pct": -1.71,
    "change_30d_pct": 6.23
  },
  "technicals": {
    "rsi_14": 43.29,
    "sma_20": 160.87,
    "sma_50": 152.22,
    "macd": 1.975,
    "macd_signal": 2.822,
    "macd_histogram": -0.847,
    "bb_upper": 164.16,
    "bb_lower": 157.59,
    "price_vs_sma20_pct": -0.89,
    "price_vs_sma50_pct": 4.75,
    "volume_ratio": 0.79
  },
  "fundamentals": {
    "market_cap": 489038708736,
    "pe_ratio": 19.592665,
    "forward_pe": 19.149055,
    "price_to_book": 6.160804,
    "price_to_sales": 5.307043,
    "profit_margin": 27.26,
    "operating_margin": 30.2,
    "roe": 33.62,
    "roa": 8.26,
    "revenue_growth": 6.8,
    "earnings_growth": 91.0,
    "debt_to_equity": 57.766,
    "current_ratio": 1.074,
    "quick_ratio": 0.711,
    "dividend_yield": 258.0,
    "fifty_two_week_high": 207.81,
    "fifty_two_week_low": 140.68,
    "fifty_day_avg": 193.4922,
    "two_hundred_day_avg": 170.2741,
    "analyst_target": 203.41833,
    "analyst_recommendation": "buy",
    "num_analysts": 24,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -2.32,
    "pct_from_52w_low": 44.28
  },
  "macro": {
    "spy": {
      "price": 560.58,
      "change_1d_pct": -0.29,
      "change_7d_pct": 1.18
    },
    "vix": {
      "level": 19.8,
      "signal": "NORMAL"
    },
    "treasury_10y": {
      "yield_pct": 4.23
    },
    "dollar_index": {
      "level": 103.85
    },
    "gold": {
      "price": 3040.0
    },
    "regime": "BULL_NORMAL"
  },
  "news": [
    {
      "headline": "U.S. FDA approves TREMFYA\u00ae (guselkumab), the first and only IL-23 inhibitor offering both subcutaneous and intravenous induction options, for adult patients with moderately to severely active Crohn's ",
      "source": "Yahoo",
      "datetime": 1742508720,
      "summary": "Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has approved TREMFYA\u00ae (guselkumab), the first and only IL-23 inhibitor offering both subcutaneous (SC) and intravenous (IV) induction options, for the treatment of adults with moderately to severely active",
      "url": "https://finnhub.io/api/news?id=6d6e0dd9f22565b7dc1f5f5ede13f84ba37ac8cfd1ed9ea7a30040293a5f93d0"
    },
    {
      "headline": "Historic Dividend Outperformance",
      "source": "SeekingAlpha",
      "datetime": 1742501100,
      "summary": "For year to date performance, the biggest losers are now mostly growth factors, whereas low volatility and dividend focused ETFs are actually still in the green so far in 2025.",
      "url": "https://finnhub.io/api/news?id=2d815f08f8492faab4f61a45b3fefb9af97f61abf91363de2b42b428d645dad9"
    },
    {
      "headline": "RYBREVANT\u00ae (amivantamab-vmjw) plus LAZCLUZE\u2122 (lazertinib) significantly outperforms standard of care in first-line EGFR-mutated lung cancer with compelling new data at ELCC 2025",
      "source": "Yahoo",
      "datetime": 1742472000,
      "summary": "Johnson & Johnson (NYSE:JNJ) announced today that new data from its industry-leading oncology pipeline will be presented at the 2025 European Lung Cancer Congress (ELCC), including overall survival (OS) results from the Phase 3 MARIPOSA study evaluating RYBREVANT\u00ae (amivantamab-vmjw) plus LAZCLUZE\u2122 (",
      "url": "https://finnhub.io/api/news?id=7e9f1b09c43569634f24161cce89f6ce17b193f3314abf7e268f568f723e131c"
    },
    {
      "headline": "Defensive Stocks For Unpredictable Trump Policy",
      "source": "SeekingAlpha",
      "datetime": 1742469633,
      "summary": "Navigate market volatility with defensive stocks, bonds, and gold.",
      "url": "https://finnhub.io/api/news?id=3a7f34c516b912e4da5e6ab19d098a97e373f71f94dfa6f751a599d77a1b754c"
    },
    {
      "headline": "My Dividend Stock Portfolio: New February Dividend Record - 100 Holdings With 11 Buys",
      "source": "SeekingAlpha",
      "datetime": 1742463648,
      "summary": "February investments fell below $1,000, mainly in BDCs like Owl Rock Capital and Ares Capital, boosting annual dividend income by $77.",
      "url": "https://finnhub.io/api/news?id=468f86fd4b412eee1971a4620667bbda7347c15c7444f076c7a1ef8f0edb1137"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "4",
      "date": "2025-03-19",
      "description": "xslF345X05/wk-form4_1742429234.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000103/xslF345X05/wk-form4_1742429234.xml"
    },
    {
      "form": "4",
      "date": "2025-03-06",
      "description": "xslF345X05/wk-form4_1741297319.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000095/xslF345X05/wk-form4_1741297319.xml"
    },
    {
      "form": "4",
      "date": "2025-03-06",
      "description": "xslF345X05/wk-form4_1741297124.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000093/xslF345X05/wk-form4_1741297124.xml"
    },
    {
      "form": "4",
      "date": "2025-02-26",
      "description": "xslF345X05/wk-form4_1740613359.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000086/xslF345X05/wk-form4_1740613359.xml"
    },
    {
      "form": "8-K",
      "date": "2025-02-26",
      "description": "d863514d8k.htm",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000119312525036773/d863514d8k.htm"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}